NIAMS Clinical Trial Implementation Cooperative Agreement
UpcomingNational Institutes of Health · Opportunity number PAR-28-031 · Forecast
Eligibility
Nonprofits are listed as eligible applicants.
- Small businesses
- Private institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Special district governments
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Independent school districts
- Native American tribal governments (Federally recognized)
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- City or township governments
- State governments
- Public housing authorities/Indian housing authorities
- For profit organizations other than small businesses
- Public and state controlled institutions of higher education
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Description
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the Clinical Trial Cooperative Agreement Program within the mission areas of the institute. This Notice of Funding Opportunity (NOFO) solicits cooperative agreement applications for implementation of investigator-initiated, single or multi-site, interventional clinical trials (all trial phases). Investigators who have completed all necessary preparation (e.g., the trial design, protocol synopsis, data analysis plan, etc.) through other means may apply for a NIAMS Cooperative Agreement Clinical Trial. The first phase is designed to allow the investigators to prepare the final aspects needed to start the trial, (e.g., establishing the single IRB (sIRB), contracts and reliance agreements with sites, hiring of staff, etc.). Transition to the second phase to begin the trial is dependent upon completion of the phase 1 milestones proposed by the investigator and approved by NIAMS. Phase 1 projects that meet their milestones will be administratively considered by NIAMS and prioritized for transition to the second phase. NIAMS expects trials to be hypothesis-driven and have the potential for high clinical impact within the research mission of NIAMS.
Funding
| Total program funding | Not listed |
|---|---|
| Award floor | $250,000 |
| Award ceiling | Not listed |
| Category | Health |
| Assistance listing | 93.846 |
Official sources
Last verified on Grants.gov Nov 4, 2026. Grantvello is not affiliated with Grants.gov or National Institutes of Health. The notice on Grants.gov is the binding text.